GlassScriptPhysician profile
Dino Santacroce
NPI 1770749830
$4,783.21
in general payments reported to CMS, 2019-2025
34 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $77.29 · 2021: $797 · 2022: $897 · 2023: $500 · 2024: $632 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $767.17 | 2019-2025 | Myrbetriq, Xtandi |
| Sumitomo Pharma America, INC. | $539.55 | 2023-2025 | Orgovyx, Gemtesa |
| Blue Earth Diagnostics | $498.51 | 2019-2025 | Posluma |
| Janssen Biotech, INC. | $407.63 | 2019-2025 | Erleada |
| Pfizer INC. | $394.54 | 2019-2025 | |
| Myovant Sciences INC. | $391.30 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $231.16 | 2019-2025 | Provenge |
| Histosonics, INC. | $222.23 | 2025 | |
| Angiodynamics, INC. | $144.32 | 2022 | |
| Urogen Pharma, INC. | $139.74 | 2022-2025 | |
| Urovant Sciences INC | $132.30 | 2021-2022 | |
| Antares Pharma, INC. | $120.60 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Boston Scientific Corporation | $107.41 | 2019-2024 | |
| Tolmar Pharmaceuticals, INC. | $66.93 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $65.00 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $57.00 | 2020-2022 | |
| Olympus America INC. | $49.02 | 2019-2025 | Itind System |
| Travere Therapeutics, INC. | $48.83 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $42.25 | 2023-2024 | Pylarify |
| Ferring Pharmaceuticals INC. | $40.15 | 2019-2025 | Adstiladrin |
| Allergan, INC. | $39.11 | 2019-2021 | |
| Abbvie INC. | $35.65 | 2022-2023 | Botox |
| Astrazeneca Pharmaceuticals LP | $31.88 | 2025 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $31.65 | 2023-2025 | |
| Verity Pharmaceuticals INC. | $26.98 | 2025 | Tlando |
| Immunitybio, INC. | $24.11 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.20 | 2019 | |
| Halozyme INC | $17.81 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $16.90 | 2025 | |
| Merck Sharp & Dohme LLC | $15.82 | 2021 | |
| Tolmar, INC. | $15.00 | 2025 | Jatenzo, Eligard |
| Teleflex LLC | $14.13 | 2022 | |
| Endo Pharmaceuticals INC. | $13.96 | 2019 | |
| Metuchen Pharmaceuticals | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dino Santacroce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.